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Summary 
The role of cell-mediated cytotoxicity in  the  complex pathophysiology of graft-versus-host 
disease  (GVHD) has remained poorly defined for several decades. We transplanted T  cells from 
Fas-ligand  (FasL)-defective and perforin-deficient mutant donor mice into lethally irradiated 
MHC-matched allogeneic recipient mice to characterize the role of cell-mediated cytotoxicity 
in GVHD. Although recipients of allogeneic FasL-defective donor T  cells underwent severe 
GVHD-associated  cachexia,  they  exhibited  only  minimal  signs  of hepatic  and  cutaneous 
GVHD pathology. Recipients ofperforin-deficient allogeneic donor T  cells developed signs of 
acute GVHD, but the time of onset was significantly delayed. These findings demonstrate that 
Fas-mediated anti-recipient cytotoxicity may be critical for the development of hepatic and cu- 
taneous GVHD, but is not required for GVHD-associated cachexia.  In addition,  perforin- 
mediated anti-recipient cytotoxicity appears to play an important role in the kinetics of GVHD 
pathophysiology, but is not required for GVHD-associated tissue damage. 
A 
llogeneic  bone  marrow  transplantation  (BMT)  1 has 
greatly expanded as a  clinical treatment modality for 
several disorders of hematopoiesis and certain hematologi- 
cal malignancies (1). Graft-versus-host disease  (GVHD) re- 
mains a principal complication following allogeneic BMT 
occurring in up to 75% of recipients  of unmanipulated HLA- 
matched  marrow  (2).  The  immunopathophysiology  of 
GVHD is complex, and is generally considered to involve two 
phases:  an afferent (inductive) phase, and an efferent (effec- 
tor) phase (3). In the afferent phase, mature T  cells present 
in the donor marrow inoculum recognize antigenic dispari- 
ties  expressed  on recipient tissues resulting  in  alloactivation 
and proliferation of the allogeneic donor T cells. In the effer- 
ent phase,  inflammatory reactions may develop in specific 
host  target  tissues  such  as  skin,  liver,  and  gastrointestinal 
tract that are characterized by mononuclear cell infiltration 
and histopathological damage  (4).  Studies of experimental 
models ofaUogeneic BMT using T cell-depletion have dem- 
onstrated that mature T  cells must be present in the donor 
marrow inoculum in order to induce GVHD, and several 
clinical studies  have  confirmed this  finding  (5,  6).  How- 
ever, the precise role of T  cell-mediated anti-recipient cy- 
1Abbreviations used in this paper: BMT, bone marrow transplantation; DN, 
double negative; FasL, Fas ligand; GVHD, graft-versus-host  disease. 
totoxicity in the pathophysiology of GVHD remains con- 
troversial (7-13). 
Recently, it has been demonstrated that perforin-depen- 
dent cytolysis and Fas-mediated apoptosis together consti- 
tute the major mechanisms of short-term T  cell-mediated 
cytotoxicity (14-16).  T  cells from mice which are homo- 
zygous for the gld (generalized lymphoproliferative disease) 
mutation are known to express a functionally defective Fas 
ligand (FasL) molecule which is not capable of transducing 
an apoptotic signal to Fas-bearing target cells (17). The per- 
forin-deficient (perforin 0/0) mutant mouse strain was  de- 
veloped by homologous recombination in a B6 embryonic 
stem cell line,  and bred to  homozygosity on a  C57BL/6 
background (18). We have transplanted T  cells from FasL- 
defective (gld) and pefforin-deficient (perforin 0/0)  donor 
mice into lethally irradiated MHC-matched allogeneic re- 
cipient mice to determine the role of these cytotoxic path- 
ways in acute GVHD. 
The present studies demonstrate that Fas-mediated cyto- 
toxicity plays  an  essential role in  the  pathophysiology of 
hepatic and cutaneous GVHD, but is not required for GVH- 
induced  cachexia.  Furthermore,  the  absence  of perforin- 
mediated cytotoxicity significantly delays the onset of GVHD, 
but  does  not  prevent  or  diminish  GVHD.  These  results 
suggest that certain local processes of GVHD such as tissue 
damage are separable from the systemic process of cachexia. 
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totoxic pathways appear to act during different stages in the 
complex pathophysiology of GVHD.  The  role  of inflam- 
matory cytokines is discussed. 
.Materials  and Methods 
Mice.  C57BL/6J (H-2b), B6.SmnC3H-gld (H-2b), LP/J (H-2b), 
and C3H.SW (H-2  b) mice were obtained from Jackson Labora- 
tory (Bar Harbor, ME).  Pefforin-deficient C57BL/6  mice  (B6- 
pefforin 0/0)  were  obtained from D.  K~igi and H.  Hengartner 
(University of Zfirich, Switzerland)  and B.  Ledermann  and  K. 
Bfirki (Sandoz Pharma Ltd., Basel, Switzerland). B6-pefforin 0/0 
mice  were  propagated at  the  University  of Miami  School  of 
Medicine Specialized Animal Facility and were maintained in a 
pathogen-free colony until use. 
Preparation of Cells.  Bone marrow cells were aspirated from the 
femurs and tibias of donor mice. T  cells were depleted from the 
bone  marrow  by incubation with  anti-Thyl.2  mAb  (30-H-12 
culture supernatant) at 1:5 dilution and 4~  for 30 rain followed 
by  Low-Tox  M  complement  (Accurate  Chemical  Co.,  West- 
bury,  NY)  at  1:20  dilution and  37~  for  45  rain.  Spleen and 
lymph node cells were harvested, pooled, and treated with anti- 
B220 mAb (14.8  culture supernatant) at  1:2.5  dilution and 4~ 
for 30 rain, followed by a secondary mouse anti-rat mAb (18.5 
ascites) at 1:50 and 4~  for an additional 30 rain. The labeled cells 
were then  treated with rabbit complement at  1:10  dilution and 
37~  for 45  rain to remove B  cells and enrich for T  cells. This 
procedure routinely enriches the  T  cell population to levels of 
purity between 75-80% as determined by flow cytometric analysis. 
Assay  for GVHD.  Recipient mice were exposed to 900 cGy 
TBI from a 6~  source at a dose rate of 50 cGy/min 24 h before 
the BMT.  In murine models of GVHD, precise numbers of ma- 
ture allogeneic donor T  cells are routinely added together with 
bone  marrow  to  induce  lethal  acute  GVHD.  The  severity of 
GVHD  correlates  directly with  the  number  of donor  T  cells 
transplanted (5). The number of donor T  cells was selected based 
upon the ability of the wild-type inoculum to induce characteris- 
tic signs of severe acute GVHD with an incidence of 100% in ei- 
ther donor/recipient strain combination. We transplanted 1 ￿  107 
donor T  cells in the B6-+LP combination, and 2  ￿  107 donor T 
ceils in the B6--)C3H.SW combination. To ensure reproducible 
results,  the number of CD3 + T  cells in the donor inoculum was 
precisely quantified by flow cytometry for each BMT.  Precisely 
the  same  numbers  of CD3 §  T  cells  from wild-type, perforin- 
deficient, or FasL-defective B6 donors were added to the T cell- 
depleted bone marrow cells (5-10 ￿  106) from normal wild-type 
B6 donors and injected together into irradiated recipient mice in- 
travenously via the lateral tail vein in a volume of 0.5 cc. Mice re- 
ceiving transplants were  distributed into groups  containing 4-8 
mice per group in each experiment. Recipients were maintained on 
acidified water (pH 3.0) containing antibiotics (100 mg/L neomy- 
cin sulfate,  10 mg/L polymyxin B) from day -3  to day 14 post- 
BMT. Recipient mice were monitored for clinical signs of GVHD 
including weight loss,  skin lesions, alopecia, diarrhea,  hunched 
posture, and mortality. Representative mice were killed at various 
times post-BMT to harvest tissues for histopathological analysis. 
Histopathology.  Skin and liver sections were  harvested from 
recipients at various intervals after BMT.  Tissues were placed in 
10% buffered formalin phosphate (Fisher Scientific, Orlando, FL). 
The fixed tissues were paraffin embedded, sectioned, and stained 
with hematoxylin and eosin by the core service of the Depart- 
ment of Comparative Pathology at the University of  Miami School 
of Medicine. Slides were coded and examined in a blinded fash- 
ion by NHA, and the tissue histology was graded. 
Immunophenotyping.  Pooled spleen and lymph node cells were 
stained with FITC-conjugated anti-CD3 mAb (145-2C11) or bi- 
otinylated anti-B220 mAb (RA3-6B2) obtained from PharMingen 
(San  Diego,  CA).  Briefly, 0.5-1  ￿  105  cells were  washed  in 
FACS  |  buffer (PBS with 1% BSA, 0.02% sodium azide), then in- 
cubated with the FITC-conjugated and biotinylated mAbs for 20 
min on ice. Cells were again washed in FACS  |  buffer and incu- 
bated with  streptavidin-PE (Fisher Scientific,  Orlando,  FL).  The 
stained cells were resuspended in FACS  |  buffer at 2  ￿  104/ml 
and analyzed on a FACScan  |  flow cytometer (Beckton Dickinson, 
San Jose, CA). Data was analyzed within a gate established for Iym- 
phocytes using forward (180 ~  and side (90  ~  angle light scatter. 
Lymphocyte Stimulation Assay.  The enriched donor T cell pop- 
ulations were cultured 2 d in the presence of either soluble anti-CD3 
mAb (2C11-145 culture supernatant) at 10% (vol/vol) or 5 Ixg/ml 
concanavalin A  (Sigma Chemical Co., St. Louis, MO) to induce 
polyclonal activation.  Mixed lymphocyte reactions were performed 
in which the enriched donor T cells were cultured 5 d at a 1:1 ratio 
with irradiated whole C3H (H-2  k) spleen cells to assess altoreactiv- 
ity. Proliferative responses were determined by measuring [3H]thy- 
midine incorporation following a 6-8-h pulse label period. 
Results 
Donor T Cells  from B6-gld Mice Are Phenotypically and Func- 
tionally Normal.  Mice  homozygous  for  the gld  mutation 
develop lymphadenopathy characterized by progressive ac- 
cumulation of functionally anergic B220+,  CD4-,  CD8- 
double negative (DN) T  cells with significant numbers ap- 
pearing after 6 wk of age (19, 20). To ensure that we were 
not  transplanting  significant  numbers  of  non-functional 
B220 +  DN T  cells, we used B6-gld mice which were 5-6 wk 
of age as donors. In addition, all detectable DN T  cells and 
most B  cells were  removed by treating spleen and lymph 
node  ceils  with  anti-B220  mAb  (14.8)  and  complement 
that  concurrently  enriched  the  phenotypically  normal  T 
cells  (Fig.  1  A).  Notably,  the  RA3-6B2  anti-B220  mAb 
used for immunophenotyping recognizes an epitope that is 
distinct from the epitope recognized by the 14.8 anti-B220 
mAb, and binding of 14.8 does not block subsequent bind- 
ing oftLA3-6B2 (21). Syngeneic donor mice, wild-type al- 
logeneic  donor  mice,  and  perforin-deficient donor  mice 
were  6-8  wk  of age.  All donor  T  cell populations  were 
prepared in the same fashion, and exhibited similar cellular 
subpopulations as determined by phenotypic analysis (data 
not shown). 
To  confirm that the enriched T  ceil population purified 
from the gld donor mice was functionally competent, these 
cells were cultured in vitro in the presence of either soluble 
anti-CD3  mAb  (2Cl1-145),  concanavalin A, or irradiated 
allogeneic  (C3H)  spleen cells.  The  proliferative responses 
of the gld T  cells to  these polyclonal and  alloantigen-spe- 
cific stimuli was within normal limits compared to wild-type 
B6 T  cells (Fig. 1, B and C). 
Marked  Reduction of Rash  but High  Incidence of Cachexia 
and Mortality after Transplantation of FasL-Defective Allogeneic 
T Cells.  Fig. 2 shows results from one representative trans- 
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Figure 1.  Phenotypic and func- 
tional analysis of B6-gld T  cells. 
(A)  Flow cytometric  analysis of 
pooled  spleen  and lymph node 
cells from wild-type B6 and B6- 
gld donor mice  before  and after 
treatment with  anti-B220  (14.8) 
mAb and complement.  The ab- 
normal CD3+B220+  lympho- 
cytes represent only a small per- 
centage  (3.1%)  of  spleen  and 
lymph  node  cells from  B6-gld 
donor  mice  before  treatment, 
and  these  cells are  absent  after 
treatment. The CD3+B220- T 
cell populations are enriched fol- 
lowing this procedure. (13) Poly- 
clonal activation of enriched do- 
nor  T  cell populations.  The 
normal  B6  and B6-gld T  cells 
were  cultured  2  d  in the  pres- 
ence  of either soluble anti-CD3 
(2Cl1-145) mAb culture  super- 
natant at 10% (vol/vol) or 5 p,g/ml 
concanavahn A. Proliferative re- 
sponses by both T  cell popula- 
tions were within normal limits. 
Data are shown from a single rep- 
resentative experiment,  and col- 
umns represent mean incorpora- 
tion values among quadruplicate 
wells. (C) Mixed lymphocyte re- 
action  by  the  T  cell-enriched 
donor  lymphocyte  populations. 
The B6 and B6-gld  donor T cells 
were  cultured  5 d at a 1:1 ratio 
with  irradiated  C3H  (H-2  k) 
spleen cells as a source of alloan- 
tigen.  Both  T  cell  populations 
responded similarly to allogeneic 
stimulation￿9 
plant experiment. All LP recipients ofsyngeneic T  cells and 
marrow survived and regained normal body weight shortly 
after the transplant (Fig. 2).  In contrast, all LP recipients of 
wild-type allogeneic B6 T  cells developed acute GVHD with 
severe weight loss and 100% mortality (Fig.  2). Recipients 
of FasL-defective B6-gld  T  cells also exhibited severe weight 
loss and 100% mortality, indicating that they were undergo- 
ing a systemic graft-versus-host reaction (Fig. 2). 
Mice  of the  C3H.SW  (H-2  b)  strain were  transplanted 
to confirm the finding that FasL-defective T  cells are capable 
of inducing a  systemic  GVH  reaction in a  second MHC- 
matched  allogeneic  donor/recipient  strain  combination. 
Again,  all  C3H.SW  recipients  of syngeneic  T  cells  and 
marrow  regained normal body weight  rapidly  after  trans- 
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plant. In contrast, all (100%)  recipients of wild-type B6 or 
B6-gld T  cells exhibited severe cachexia (data not shown). 
Recipient  mice  were  monitored  for  clinical  signs  of 
acute  GVHD  following the  transplant￿9 Neither  C3H,SW 
(Fig 3 A) nor LP recipients ofsyngeneic T  cells ever devel- 
oped any clinical signs of GVHD.  The  chnical appearance 
of mice that  received wild-type allogeneic B6  T  cells was 
characteristic of acute GVHD  including marked weight loss, 
hunched  posture,  desquamative  rash,  and patchy  alopecia 
(Fig. 3  /3).  In striking contrast, none of the mice receiving 
FasL-defective B6-gld  T  cells  ever  exhibited  any  signs  of 
skin or coat involvement at any time after BMT although all 
developed severe weight loss (Fig. 3  C). Results of clinical 
observations of groups of C3H.SW  and LP mice from five A  100  " 
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Figure 2.  Body weight and  mortality  during acute  GVHD  after aUo- 
geneic bone  marrow  transplantation  of cytotoxically defective  T  cells. 
Lethally irradiated LP recipient mice (seven per group) were transplanted 
with  l  ￿  107 T  ceils from either syngeneic  (LP), wild-type allogeneic 
(B6), or FasL-defective allogeneic (B6-gld) donor mice. After BMT, recipi- 
ents were monitored for mortality (A) and weight loss (B). Mice receiving 
either wild-type B6 or B6-gld T cells developed acute GVHD with 100%, 
mortality and severe weight loss, while recipients ofsyngeneic T cells and 
marrow survived and rapidly regained normal body weight. 
independent  experiments  confirm  an  absence  of  clinical 
cutaneous  GVHD  (0/32)  despite  the  presence  of cachexia 
(32/32)  following BMT  with  FasL-defective donor T  cells 
(Table  1). 
Marked Delay of G VHD and Mortality  after Transplantation 
of Petforin-Deficient Allogeneic T  Cells.  An  MHC-matched 
model  of  allogeneic  BMT  was  employed  to  determine 
whether perforin-deficient T  cells could induce severe acute 
GVHD  across  minor  histocompatibility  barriers.  Lethally 
irradiated LP  (H-2 b)  mice  were  transplanted  with  1  X  107 
T  cells and  bone  marrow  from wild-type  or perforin-defi- 
cient B6  (H-2 b)  donor  mice.  Recipients  of syngeneic  (LP) 
T  cells  maintained  normal  body  weight  and  did  not  de- 
velop signs of GVHD  (Figs. 4  and 5, A),  The  mice receiv- 
ing  wild-type  B6  T  cells  developed  signs  of severe  acute 
GVHD  within  28  d  after the  transplant  (Figs.  4  and  5,  B). 
The  recipients of T  cells from B6-perforin  0/0  donors  also 
developed signs of severe acute GVHD  includin~ weight loss 
Figure 3.  Clinical  appearance  of C3H.SW recipient mice 28  d  after 
BMT.  (A) Recipients of 2  ￿  107 syngeneic  (C3H.SW) T  cells regained 
normal body weight and showed no signs of acute GVHI). (B) Mice that 
received 2 ￿  107 wild-type allogeneic (t36) T cells exhibited severe weight 
loss, hunched posture, patchy alopecia,  and desquamative  rash on  ears, 
paws, trunk, and tail. (C)Recipients of 2 ￿  107 FasL-defective allogeneic 
(B6gld) T  cells also exhibited severe weight loss, but none ever devel- 
oped any signs of rash or alopecia throughout all studies. 
(Fig. 4  B),  alopecia, hunched  posture,  diarrhea,  and desqua- 
mative skin rash with an incidence of 100%  (Fig. 5  C).  How- 
ever,  the  average  time  of onset  of these  signs  was  delayed 
approximately twofold compared  to the  recipients of wild- 
type cells. The  delay of onset in the recipients  of perforin- 
deficient T  cells was also apparent in the kinetics of mortal- 
ity.  There  was  a  more  than  twofold  increase  in  the  mean 
survival  time  (65.3  vs 23.7  d)  in  the  perforin-deficient  re- 
cipient  group  compared  to  the  wild-type  recipient  group 
(Fig.  4  A).  Results  from  seven  independent  experiments 
using either  C3H.SW  or LP  strain mice  as  recipients  con- 
firmed  that  transplantation  of perforin-deficient  allogeneic 
2648  Perforin and FasL-mediated Cytotoxicity in Acute GVHD Table 1.  Summary  of Clinical Signs  from Seven Independent Bone 
Marrow Transplant Experiments 
Cachexia  Rash, Mopecia 
LP---)LP  0/21  0/21 
B6----)LP  34/34  34/34 
B6-perforin 0/0--~LP  34/34  34/34 
B6-gld--)LP  21/21  0/21 
C3H.SW---)C3H.SW  0/9  0/9 
B6---->C3H.SW  15/15  15/15 
B6-perforin 0/0--)C3H.SW  14/14  14/14 









|  t 
10  20 
I.~  I 
~t 




I  ......... 
￿9 .........  i 
i 
I 
|  i  | 
30  40  gO 




t  ~  'w  | 
60  70  80  90 
Recipient mice were examined thrice weekly for clinical signs of acute 
GVHD including cachexia, alopecia, and desquamative rash. Results are 
expressed as the number of mice exhibiting signs compared to the total 
number  of mice examined. Notably, the recipients of FasL-defective 
B6-gld T cells all developed cachexia, but none exhibited any signs of 
alopecia or rash throughout the study. 
T  cells uniformly produces acute GVHD with a significant 
delay in time of onset (Table  1). 
Cutaneous  G VHD Is Markedly Diminished  in the Absence of 
FasL-mediated  but Not Petforin-mediated Anti-Recipient  Cyto- 
toxicity.  Skin sections were harvested from representative 
mice at 28 d post-transplant  to determine  if the absence of 
perforin or Fas-mediated anti-recipient  cytotoxicity would 
effect  the  incidence  or  severity  of GVHD-associated  pa- 
thology. Cutaneous sections from recipients ofsyngeneic T 
cells  were  unremarkable  (Fig.  6  A).  Skin  sections  from 
C3H.SW recipients of 2  X  107 wild-type B6 T  cells exhibited 
severe inflammation with mononuclear cell infiltrates,  der- 
mal  fibrosis,  loss of hair follicles,  and  epidermal  hypertro- 
phy  consistent  with  cutaneous  GVHD  (Fig.  6  B).  In 
marked contrast, skin from C3H.SW recipients ofB6-gld T 
cells  exhibited  evidence  of  only  minimal  inflammation 
(Fig.  6  C).  On day 52,  cutaneous sections from recipients 
of perforin-deficient  B6  T  cells  exhibited  alterations  that 
were identical  in  character  and  severity to those  observed 
in recipients  of wild-type B6 T  cells  on day 28  (Fig. 6 D). 
A  second MHC-matched  donor/recipient  strain combina- 
tion  (B6-4LP)  was  employed  to  confirm  this  differential 
pattern  of tissue  damage  after  transplantation  of cytotoxi- 
cally defective T  cells.  These studies also demonstrated that 
cutaneous  GVHD  develops  in  the  absence  of perforin- 
mediated  anti-recipient  cytotoxicity,  but  is  markedly  re- 
duced in the absence of FasL-mediated anti-recipient cyto- 
toxicity (data not shown). 
Hepatic  GVHD  Is Markedly  Diminished  in  the Absence of 
FasL-mediated  but Not Petforin-mediated Anti-Recipient  Cyto- 
toxicity.  Liver sections  were  harvested  from recipients  at 
various  time  intervals  following transplantation  to investi- 
gate  how the  absence  of Fas  and  perforin-mediated  cyto- 
toxicity  affected  the  pathophysiology of hepatic  GVHD. 
Sections ofhver from C3H.SW recipients ofsyngeneic T  cells 
2649  Baker et al. 
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Figure 4.  Body weight and mortahty during acute GVHD following 
allogeneic bone marrow transplantation. Lethally irradiated LP recipient 
mice (seven per group) were transplanted with 1 ￿  107 T cells from ei- 
ther syngeneic (LP), wild-type allogeneic (B6), or pefforin-deficieut allo- 
geneic (B6-perforin 0/0) donor mice. After BMT, recipients were moni- 
tored for mortality (A) and weight loss (B). Recipients of syngeueic T 
cells and marrow survived and rapidly regained normal body weight. 
Mice receiving either wild-type B6 or B6-perforin 0/0 T cells developed 
acute GVHD with 100% mortality and severe weight loss. However, the 
time of onset for weight loss was delayed and the mean survival time was 
increased approximately twofold in the recipients ofperforin-deficient al- 
logeneic T cells. 
28 d post-transplant were unremarkable (Fig. 7 A). Hepatic 
sections  from. recipients  of 2  ￿  107  wild-type B6  T  cells 
exhibited a marked infiltrate of predominantly PMNs around 
bile  ducts with associated partial  inflammation and fibrosis 
that  was  evaluated  as  severe  acute  cholangitis  consistent 
with  hepatic  GVHD  (Fig.  7  B).  In marked  contrast,  liver 
sections from C3H.SW recipients of B6-gld T  cells  exhib- 
ited evidence of only minimal involvement (Fig. 7  C). It is 
important to note that at no time after transplant of B6-gld 
T  cells did the liver sections of these recipients  exhibit sig- 
nificant hepatic pathology. On day 52, hepatic  tissues  from 
recipients  of perforin-deficient B6 T  cells  exhibited severe 
cholangiohepatitis  (Fig.  7  D).  A  second  MHC-matched 
donor/recipient  strain  combination  (B6---~LP) was  em- 
ployed to confirm this differential pattern of tissue damage Figure  5.  Chnical appearance of LP recipient mice 29 d after BMT. 
(A) Recipients of 1 ￿  107 syngeneic (LP) T cells regained normal body 
weight and showed no signs of acute GVHD. (~ Mice that received 1 ￿ 
107 wild-type allogeneic (B6) T cells exhibited severe weight loss, hunched 
posture, patchy alopecia, and desquarnative rash on ears, paws, trunk, and 
tail. (C)R.ecipients  of 1 ￿  107 pefforin-deficient  allogeneic (B6-pefforin  0/0) 
T cells 70 d after transplant also exhibited hunched posture, patchy alope- 
cia, and desquamative rash on ears, paws, trunk, and tail. 
after transplantation  of the  cytotoxically  defective  T  cells. 
These studies also demonstrated that hepatic GVHD devel- 
ops in  the  absence  of perforin-mediated  anti-recipient  cy- 
totoxicity, but is markedly reduced in the absence of FasL- 
mediated anti-recipient  cytotoxicity (data not shown). 
There is evidence in the literature  that epithelial damage 
in gastrointestinal  GVHD  lesions is characterized by apop- 
tosis and DNA fragmentation  (22). Therefore, we were in- 
terested  to  examine  the  role  of Fas-mediated  cytotoxicity 
in  gastrointestinal  GVHD.  Clinical  evidence  of diarrhea 
was  observed  in  some  but  not  all  recipients  of wild-type, 
FasL-defective, and perforin-deficient allogeneic T  cells. In 
addition,  histopathological evidence of acute colitis and en- 
teritis  was occasionally observed in recipients  of wild-type, 
FasL-defective,  and  perforin-deficient  allogeneic  T  cells 
(data not shown).  Therefore, defects in individual cytotoxic 
pathways  did  not  consistently  abrogate  either  clinical  or 
histopathological  sequelae  associated  with  gastrointestinal 
GVHD. 
Recipients of FasL-defective Allogen& T  Cells Do Not Exhibit 
Lymphoid Atrophy.  Recipient splenic lymphocytes were har- 
vested and analyzed by flow cytometry 28 d  after transplant 
to examine the status of the lymphoid compartment. Table 2 
shows the numbers of spleen cells recovered from these re- 
cipients.  Mice receiving wild-type or perforin-deficient  al- 
logeneic T  cells exhibited profoundly  decreased spleen cell 
recoveries  that are typically observed in  murine  models  of 
acute GVHD  (Table 2). Notably,  recipients of FasL-defec- 
tive T  cells exhibited  a  somewhat increased  spleen  cell re- 
covery, but  did not  exhibit  evidence  of uncontrolled  lym- 
phoproliferative  disease  (Table  2).  These  findings  have 
been observed in seven independent  transplantation  exper- 
iments. 
Mice  that received syngeneic  (C3H.SW)  T  cells  exhib- 
ited normal percentages of B220+  cells (54.0%)  and CD3+ 
ceils  (23.1%)  in the spleen  (Fig.  8  E).  Light scatter profiles 
of spleen  ceils  from  recipients  of wild-type  allogeneic  T 
cells  (Fig.  8  /3)  showed  a  markedly reduced  lymphoid  cell 
population  (Region  1),  which  was  comprised  of  71.3% 
CD3+  T  cells (Fig. 8 F). This pattern is consistent with acute 
GVHD  (23). A very similar pattern of lymphoid hypoplasia 
and spleen cell phenotype was observed in spleens from re- 
cipients  of perforin-deficient  allogeneic  T  cells  in  which 
81.2% of the gated cells were CD3+  (Fig.  8,  C  and  G).  In 
contrast, the degree of lymphoid hypoplasia was less severe in 
the recipients of FasL-defective T  cells  as determined by light 
scatter (Fig.  8  D). In addition,  the percentage orB220+  cells 
was increased  to  28.0%  in the  recipients  of FasL-defective T 
cells  (Fig.  8  H)  compared to 2.6%  in the recipients  of wild- 
type T  cells.  However, as expected the percentage of CD3 + 
T  cells (54.2%) was elevated in the recipients of FasL-defective 
T  cells consistent with a GVHD-associated expansion  of al- 
loreactive donor T  cells. 
Discussion 
The  role  of cell-mediated  anti-recipient  cytotoxicity  in 
the pathophysiology of GVHD has remained poorly defined 
and controversial for several decades.  To begin resolving the 
long standing controversy regarding the role of anti-recipient 
specific cell-mediated cytotoxicity in GVHD, we have com- 
pared  the  ability  of FasL-defective,  perforin-deficient,  and 
wild-type allogeneic T  ceils to induce  severe acute  GVHD 
across non-MHC  antigenic barriers in mice.  The results of 
the present study demonstrate that Fas-mediated cytotoxicity 
plays  an important  role  in  the  pathophysiology  of hepatic 
and cutaneous  GVHD after BMT between MHC-matched 
allogeneic mice. However,  Fas-mediated anti-recipient  cy- 
totoxicity is not required for the induction  of GVHD-asso- 
ciated  cachexia,  Furthermore,  transplantation  of perforin- 
2650  Perforin a~ld FasL-mediated  Cytotoxicity in Acute GVHD Figure 6.  Histopathological analysis of skin from C3H.SW recipient mice 28 d a~er BMT with 2  X  107 T  cells. Representative recipient mice were 
sacrificed and skin sections were harvested for histopathological analysis. (A) Skin from recipients ofsyngeneic (C3H.SW) T  cells were unremarkable. (B) 
Analysis of  skin from recipients of  wild-type allogeneic (B6) T  cells exhibited severe inflammatory infiltrates,  dermal fibrosis, loss of  hair follicles, and epi- 
dermal hypertrophy consistent with cutaneous GVHD. (C) Cutaneous sections from recipients of FasL-defective allogeneic (B6-gld) T  cells exhibited ev- 
idence of  minimal inflammatory changes or no involvement. (D) Skin from recipients ofperforin-deficient allogeneic (B6-perforin 0/0) T  cells on day 52 
post-transplant exhibited severe inflammatory infiltrates, dermal fibrosis,  loss  of hair follicles,  and  epidermal hypertrophy consistent with cutaneous 
GVHD. 
deficient T  cells results in a marked delay in onset of GVHD 
and mortality compared to  GVHD induced by wild-type 
aUogeneic T  cells. However, severe acute GVHD ultimately 
does develop with all of the classical hallmarks  of GVHD 
including hunched posture, weight loss, alopecia, rash, cho- 
langitis,  and dermatitis. 
The morphological and ultrastructural features of lesions 
in hepatic, cutaneous, and gastrointestinal GVHD have pre- 
viously been reported to involve some degree of individual 
cell necrosis, pyknotic nuclei, and apoptotic bodies consis- 
tent with  a  role for apoptosis in  GVHD-associated tissue 
damage (24-26). In addition, both liver and skin tissues are 
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known to express Fas (27), and mice injected with the anti- 
Fas monoclonal antibody Jo2 rapidly develop a fulminant 
lethal hepatitis (28).  Furthermore, it has been reported re- 
cently that expression of Fas is upregulated in epidermal tis- 
sues undergoing certain inflammatory conditions (29). Thus, 
skin  and liver could be potential targets  for FasL-bearing 
cytotoxic donor T  cells  after allogeneic BMT.  Consistent 
with  our findings  that  GVHD-associated  cholangitis  and 
dermatitis is markedly reduced in the absence of Fas-medi- 
ated cytotoxicity, we propose that this pathway may be an 
essential  step in the multi-step process that ultimately leads 
to  GVHD-associated  inflammation  and  tissue  damage  in Figure 7.  Histopathological  analysis ofhver from C3H.SW recipient mice 28 d after BMT with 2 X 107 T cells. Representative recipient mice were 
killed and liver sections were harvested for histopathological analysis. (A) Liver sections from recipients of syngeneic (C3H.SW) T cells were unremark- 
able. (B) Analysis of liver from recipients of wild-type allogeneic (B6) T cells demonstrated severe subacute cholangiohepatitis consistent with hepatic 
GVHD. (C) Hepatic sections from recipients of FasL-defective allogeneic (B6-gkO  T cells exhibited evidence of  minimal inflammatory  changes or no in- 
volvement. (D) Liver sections from recipients of perforin-deficient allogeneic (B6-perforin 0/0) T cells on day 52 post-transplant exhibited severe subacute 
cholangiohepatitis consistent with hepatic GVHD. 
recipient  liver  and  skin  tissues.  However,  the  findings  in 
the  present  study do  not  suggest  that  Fas-mediated  cyto- 
toxicity is the only effector mechanism contributing to he- 
patic and cutaneous GVHD. 
While  hepatic  and  cutaneous  pathology  was  markedly 
reduced in recipients of FasL-defective donor T  cells,  these 
recipients exhibited severe cachexia and lost on average 35% 
of their initial body weight and virtually all body fat by day 
28  post-BMT.  Tumor necrosis factor (TNF-~x,  cachectin) 
produced by alloactivated FasL-defective donor T  cells could 
account for the profound wasting and mortality observed in 
the recipients of the B6-gld T  cells.  TNF-~x has been iden- 
tified as a principal mediator of cachexia in rodents  (30). In 
addition,  serum levels of TNF have been shown to be in- 
creased in patients undergoing GVHD after allogeneic BMT 
(31).  Notably,  Piguet  et  al.  demonstrated  that  administra- 
tion  of anti-TNF-c~  anti-sera  markedly  reduces  recipient 
weight loss and mortality in a mouse model of GVHD (32). 
Despite significant work, it has remained difficult to rec- 
oncile  the  classical  concept  of MHC-restricted  T  cell- 
mediated cytotoxicity with the observation that highly pu- 
rified  T  cell  subset  populations  (CD4+  or  CD8§  are 
equally capable of inducing identical  GVHD pathology ir- 
respective  of class  I  or class  II expression by the target tis- 
sues (33). Consistent with our results,  one interpretation  of 
the  finding  that  either  subset  alone  can  induce  identical 
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Figure  8.  Light  scatter  and 
phenotypic  analysis  of  spleen 
cells from  C3H.SW  recipient 
mice 28 d after transplantation of 
2  ￿  107  T  cells. Spleen cells 
were  stained  with  anti-CD3- 
FITC (FL1) and anti-B220-bio- 
tin +  avidin-PE (FL2), and ana- 
lyzed within  a  gate  established 
for  lymphocytes  using  forward 
(FSC) and side (SSC) angle light 
scatter. (A  and  E)  Spleen cells 
from  recipients  of  syngeneic 
(C3H.SW)  T  cells exhibited  a 
normal light scatter and pheno- 
typic  pattern  of  CD3+  and 
B220+  cells. (B and F) Analysis 
of spleen from recipients of  wild- 
type allogeneic (B6) T cells dem- 
onstrated severe lymphoid hypo- 
plasia and  a  predominance  of 
CD3+ T cells. (Cand G) Spleen 
cells from recipients of perforin- 
deficient allogeneic (B6-perforin 
0/0)  T  cells exhibited a pattern 
of  lymphoid hypoplasia  and predominance ofCD3 + T cells that was similar to the recipients of  wild-type allogeneic T cells. (D and H) Analysis  of spleen 
cells from recipients of FasL-defective  allogeneic (B6-gld) T cells demonstrated less severe lymphoid hypoplasia (R.1) and increased numbers of B220+ 
cells compared to recipients of wild-type allogeneic T cells. 
GVHD pathology is that cytotoxic T  cells (CTL)  of either 
phenotype may effect allogeneic cytotoxicity via FasL. No- 
tably, it has recently been reported that  CD4+  CTL may 
kill primarily through the Fas pathway (34). 
It is important  to  note  that  we  have  observed no  evi- 
dence of lpr -GVH or lymphoproliferative disease in recipi- 
ents of B6-gld donor T  cells. These recipients did not de- 
velop lpr-GVH-associated  skin or liver inflammation,  nor 
did  they  develop  lpr-GVH-associated  lymphoid  aplasia 
(Figs. 6-8).  The B6-gld T  cells that were transplanted have 
a defect only in the Fas-ligand molecule resulting in an in- 
ability to kill through the Fas pathway. However, the B6- 
gld T  cells express normal levels of functional Fas antigen, 
and therefore have the potential to be regulated or deleted 
by cells of host origin such as stromal cells that may be ca- 
pable of expressing functional FasL (35).  Thus,  our obser- 
vations  are  consistent  with  the  established  finding  that 
transplantation of bone marrow from gld/gld mutant donors 
into  wild-type  recipients  does  not  induce  the  Ipr-GVH 
phenomenon (36). Moreover, the transplantation of wild-type 
B6 marrow in our studies results in the de novo generation 
of T  cells that are able to express normal non-mutant  FasL 
molecules (Baker, M.B. and R.B. Levy, manuscript in prep- 
aration).  Therefore,  wild-type  donor  marrow-derived  T 
cells that express the non-mutant  FasL could also regulate 
the gld T  cells that express a functional Fas molecule. 
The  finding that recipients of perforin-deficient alloge- 
neic T  cells exhibited clinical and histopathological signs of 
GVHD  equivalent in severity to the signs observed in re- 
cipients of wild-type allogeneic T  cells conclusively dem- 
onstrates that perforin-mediated cytotoxicity is not a  criti- 
cal effector function  during the  effector phase  of GVHD. 
Table 2.  Spleen Cell RecoveriesJ~om C3H.SW Mice 28 d after Receiving 2 X  107 Donor T Cells 
Spleen Cell 
Recovery  CD3+ B220-  B220+  CD3-  CD3+ B220+ 
C3H.SW-->C3H.SW  41.3  ￿  106  9.5  X  106  22.3  ￿  106  0.32  X  106 
B6-->C3H.SW  6.9 X  106  4.9 X  106  0.18  ￿  106  0.44  ￿  10  s 
B6-perforin 0/0-->C3H.SW  5.2 ￿  106  4.2 ￿  106  0.14 X  106  0.21  ￿  10 s 
B6-gld-->C3H.SW  12.6  X  106  6.8 ￿  106  3.5 ￿  106  0.23  ￿  106 
Lymphocyte subpopulation numbers are calculated based on percentages derived from phenotypic analysis (see Fig. 8). Significantly increased num- 
bers of phenotypically normal B cells (B220+CD3-) are recovered from recipients of FasL-defective allogeneic T cells compared to recipients of 
wild-type and perforin-deficient  allogeneic T cells. Notably,  mice receiving B6-gld T cells did not exhibit an abnormally expanded population  of 
B220+ DN T cells (B220+CD3+). 
2653  Baker et al. We conclude that perforin-mediated donor anti-host cyto- 
toxic function is not an absolute requirement for the devel- 
opment of GVHD across minor histocompatibility barriers. 
While perforin-deficient allogeneic T cells are clearly ca- 
pable  of inducing severe  acute  GVHD,  the  recipients  of 
these cells have consistently exhibited a significant delay in 
the time of onset of clinical signs  associated with GVHD 
and a prolonged MST. This finding suggests  that perforin- 
mediated cytotoxicity may be playing an important role in 
the early post-transplant period during the afferent phase of 
GVHD that could lead to a shift in kinetics without dimin- 
ishing  the  ultimate  severity of tissue  damage  and  clinical 
signs of GVHD. Notably, preliminary results in our labora- 
tory  suggest  that  transplantation  of perforin-deficient T 
cells at a dose twofold higher than the wild-type T cells re- 
suits in onset of GVHD with no delay compared to the re- 
cipients of the lower dose of normal ceils.  In addition, we 
have found that when very low numbers of bone marrow- 
derived perforin-deficient T  cells are transplanted the onset 
of GVHD is delayed indefinitely (37). 
One potential explanation for the delayed onset of GVHD 
in recipients of pefforin-deficient T  cells is that perforin- 
mediated cytotoxicity may accelerate and amplify the do- 
nor anti-host immune reaction. This may occur as a result 
of the release of inflammatory cytoplasmic contents follow- 
ing cytolysis of host target cells.  When perforin-mediated 
anti-host cytolytic activity is absent, the resulting alloagres- 
sive  reaction  might  be  slowed.  Alternatively,  perforin- 
mediated donor anti-host cytotoxic activity may be critical 
for  overcoming residual  host  resistance  in  the  recipient. 
Thus, in the absence of perforin-mediated anti-host cyto- 
toxicity, host resistance would remain stronger and persist 
longer in the recipient diminishing the relative alloaggres- 
sive capacity of the perforin-deficient inoculum. 
One  advantage  of employing  genetically  modified  or 
naturally occurring mutant mouse strains as a source of donor 
T  cells is that only one cytotoxic pathway has been selec- 
tively abrogated leaving the other cytotoxic effector functions 
intact.  Cytotoxic T  cells and NK cells from perforin-deficient 
mice exhibit profoundly diminished in vitro cytolytic func- 
tion, but retain the ability to effect Fas-mediated and TNF- 
mediated kilhng  (15).  Alternatively, the  Fas-ligand mole- 
cule expressed by T  cells from gld mice is non-functional, 
but perforin-dependent cytolytic function remains  intact. 
Therefore, these experiments were able to directly examine 
the role of each cytotoxic pathway by its absence, while si- 
multaneously confirming the function of the  other by its 
presence. Accordingly, consistent with the marked dimin- 
ishment of hepatic and cutaneous GVHD following trans- 
plantation of FasL-defective T  cells,  GVHD developed in 
these tissues following transplantation of perforin-deficient 
T  cells  because  Fas-mediated  cytotoxic function  remains 
intact. Another advantage of employing T  cells with mo- 
lecular  defects  in  cytolytic function  is  that  the  defect  is 
present in every donor cell of all phenotypes regardless  of 
how these populations may interact and contribute to the 
development of GVHD. 
Previous studies designed to examine effector functions 
in  GVHD  have  employed transplantation  of cell popula- 
tions that have been negatively selected on the basis of im- 
munophenotype (e.g.,  CD8+,  CD4+,  NKI.I+  cells).  In 
studies involving negative selection, all potential cytotoxic 
and cytokine effector functions of the depleted cell popula- 
tion are removed along with the negatively selected popu- 
lation. In contrast, the present study is designed so that the 
potential to produce multiple inflammatory cytokines such 
as IL-1, IFN-y, and TNF-o~ by the cytotoxically defective 
T  cells  remains intact.  These cytokines are known  to be 
produced  by  alloactivated  donor T  cells  during  GVHD, 
and appear to contribute significantly to both inductive and 
effector phases of GVHD (38). 
The results  of the present studies represent the first char- 
acterization of the role of Fas and perforin-mediated anti- 
recipient cytotoxic function in the pathogenesis of GVHD 
after allogeneic bone  marrow  transplantation  across  non- 
MHC genetic disparities. These results demonstrate that Fas- 
mediated cytotoxicity is required for the  development of 
hepatic  and  cutaneous  GVHD,  but  is  not  required  for 
GVHD-associated cachexia.  This  finding has  shown  that 
local and systemic effects of GVHD are separable.  Further- 
more, the results  also demonstrate that absence of perforin- 
mediated  anti-recipient  cytotoxicity does  not  prevent or 
diminish GVHD, but significantly delays the time of onset. 
We interpret this finding to indicate that while perforin- 
mediated cytotoxic function is not required for the effector 
phase of GVHD, this cytotoxic pathway appears to play a 
significant role during the inductive phase of GVHD. We 
conclude that the two major pathways of cell-mediated cy- 
totoxicity play distinct roles in the complex pathophysiol- 
ogy of GVHD, and that these roles appear to be expressed 
during different stages of GVHD pathogenesis. 
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